• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections

tetano

Editor, Senior Moderator
Front Immunol. 2019 Feb 12;10:134. doi: 10.3389/fimmu.2019.00134. eCollection 2019.
[h=1]Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections.[/h] Fusade-Boyer M[SUP]1[/SUP], Dupr? G[SUP]1[/SUP], Bessi?re P[SUP]1[/SUP], Khiar S[SUP]2[/SUP], Quentin-Froignant C[SUP]1,[/SUP][SUP]3[/SUP], Beck C[SUP]4[/SUP], Lecollinet S[SUP]4[/SUP], Rameix-Welti MA[SUP]5,[/SUP][SUP]6[/SUP], El?ou?t JF[SUP]7[/SUP], Tangy F[SUP]2[/SUP], Lajoie B[SUP]8[/SUP], Bertagnoli S[SUP]1[/SUP], Vidalain PO[SUP]9[/SUP], Gallardo F[SUP]3[/SUP], Volmer R[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The guanabenz derivative Sephin1 has recently been proposed to increase the levels of translation initiation factor 2 (eIF2α) phosphorylation by inhibiting dephosphorylation by the protein phosphatase 1-GADD34 (PPP1R15A) complex. As phosphorylation of eIF2α by protein kinase R (PKR) is a prominent cellular antiviral pathway, we evaluated the consequences of Sephin1 treatment on virus replication. Our results provide evidence that Sephin1 downregulates replication of human respiratory syncytial virus, measles virus, human adenovirus 5 virus, human enterovirus D68, human cytomegalovirus, and rabbit myxoma virus. However, Sephin1 proved to be inactive against influenza virus, as well as against Japanese encephalitis virus. Sephin1 increased the levels of phosphorylated eIF2α in cells exposed to a PKR agonist. By contrast, in virus-infected cells, the levels of phosphorylated eIF2α did not always correlate with the inhibition of virus replication by Sephin1. This work identifies Sephin1 as an antiviral molecule in cell culture against RNA, as well as DNA viruses belonging to phylogenetically distant families.


[h=4]KEYWORDS:[/h] GADD34; PKR; PPP1R15A; antiviral; broad-spectrum; eIF2α; host; virus

PMID: 30809223 PMCID: PMC6379315 DOI: 10.3389/fimmu.2019.00134
Free PMC Article
 
Back
Top Bottom